Regulatory FDA seeks permanent future for rare pediatric priority review vouchers Pharmaceutical TechnologyThe rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.RegulatoryRare DiseaseRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Technology The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability. RegulatoryRare DiseaseRead full story Post navigation Previous: Syneron raises $150m for macrocyclics, and other financingsNext: Jeito Capital secures over $1.2bn for new biopharma investments Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026